Clinical trials in Nuclear Medicine (NM) increasingly rely on complex radiopharmaceutical protocols and multidisciplinary workflows, yet the role of the Study Coordinator (SC), central to regulatory compliance, data quality, and operational efficiency, remains insufficiently mapped in Italy. A national cross-sectional survey was distributed to Italian NM Units with documented research activity. Twenty-two centers responded, providing information on SC presence, responsibilities, contractual conditions, and perceived impact on clinical research performance. SC resources were unevenly distributed: only 10 of 22 centers (45.5